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ABSTRACT 
Objective: The objective of this study was to design an effective topical treatment for oral mucositis. 
Methods: Poly-(DL-lactide-co-glycolide) (PLGA) nanoparticles (NPs) and Poloxamer407 (PLX)/Hydroxy propyl methyl cellulose (HPMC) hydrogel 
matrix (HG) were used as combined carriers for benzydamine HCL (BNZ). BNZ loaded PLGA nanoparticles were assessed for their particle size, PDI, 
zeta potential and entrapment efficiency. Scanning electron microscopy, thermosensitivity study, mucoadhesion study, in vitro release and in vivo 
investigation were used to characterize the combined BZN loaded PLGA NPs HG. 
Results: Negatively charged NPs with an average diameter of 139±4.92 nm were incorporated into PLX/HPMC HG bases. The gelation temperature 
of BZN-PLGA-NPs-HGs ranged between 31°C and 36.5°C. When diluted with saliva simulated fluid, BZN-PLGA-NPs-HGs preserved their gelation 
properties. Mucoadhesion was found lower for formulations prepared with PLX without HPMC. An increase in the concentrations of PLX from 10 to 
30% resulted in an increase in adhesion. Both PLGA-NPs and PLGA-NPs-HG provided a biphasic drug release profile while BZN-HG provided 
monophasic zero order release pattern. The in vivo study showed that animal groups treated with BZN-HG and BZN-PLGA-NPs-HG showed a 
significantly higher reduction percentage in ulcer surface area compared to those treated with BZN-PLGA-NPs. BZN-PLGA-NPs-HG group needed 10 
d of treatment to complete healing versus 16 d, 14 d and 12 d for the complete healing of groups with no treatment, treated with BZN-PLGA-NPs and 
treated with BZN-HG, respectively. 
Conclusion: BZN-PLGA-NPs-HG could represent a promising mean for the effective treatment of oral mucositis induced by cancer therapy. 
Keywords: Mucositis, PLGA nanoparticles, Thermosensitive hydrogel, Mucoadhesive hydrogel, In vivo 




Mucositis is a highly common side effect to cancer treatments [1]. It 
is characterized by painful lesions and odynophagia. Mucositis often 
degrades patients' quality of life and affects compliance with 
anticancer therapies to the extent of interrupting treatment [2-4]. 
Oral mucositis is reported in about 100% of patients on high-dose 
chemotherapy, in 80% of patients with head and neck malignancies 
and who are treated with radiotherapy and in 40% of patients 
receiving conventional doses of cytostatic chemotherapy [5]. To our 
knowledge, there is no approved method for either the prevention 
or the treatment of mucositis [2] except for some therapeutic 
strategies which depends on the use of direct cytoprotectants such 
as laser, sucralfate, corticosteroids, silver nitrate, vitamins and 
antioxidants, cryotherapy and indirect cytoprotectants including 
antimicrobial agents and haematopoietic growth factors [2]. BNZ HCl 
is a nonsteroidal drug that possesses analgesic, anesthetic, anti-
inflammatory, antipyretic and antimicrobial properties [6]. BZN is 
suggested to exert its action through suppressing selected pro-
inflammatory cytokine production which is hypothesized to be one 
major mechanism of oral mucositis [6]. BZN HCl is used as a 
mouthwash or mouth spray in a concentration of 0.15% [7], however, 
such forms show a short residence time in the buccal cavity, therefore, 
the concentration of BZN HCl on the oral mucosa cannot be 
maintained, and in turn, it is difficult to expect an effective treatment. 
Over the past few decades, there has been considerable interest in 
the development of biodegradable polymeric drug carriers. PLGA is 
one of the most attractive biodegradable synthetic polymers 
approved by the FDA for human use [8-10], for its safety profile [8], 
biocompatibility, as well as its tunable mechanical properties and 
ability to effectively deliver the drug to the target site following a 
controllable degradation into metabolite monomers, glycolic acid 
and lactic acid [8] which are further metabolized by the body via the 
Krebs cycle [11, 12]. However, when PLGA NPs are applied directly 
to the buccal mucosa, they are drained rapidly through the salivary 
action, which leads to their rapid elimination through involuntary 
swallowing [13, 14]. For this reason, the development of 
mucoadhesive preparations for buccal administration of PLGA 
nanoparticles is important. HG with mucoadhesive and 
thermosensitive properties represent a promising option, since 
mucoadhesion allow close contact with the buccal mucosa, providing 
adhesiveness and prolonging the residence time of the drug [15, 16] 
and in situ thermosensitivity allows easy application and quick 
spreading [17] of the formulation onto the site of action at room 
temperature whereas, the subsequent gelation enhance the 
hydrogel’s mucoadhesive property. Pluronic®/poloxamers are a 
group of polymers which exhibits thermos-reversible property in 
aqueous solutions. Poloxamer 407 is widely used as a gelling agent 
in the concentration range of 20 to 30%. Poloxamer 407 not only can 
self-assemble to form micelles but is also known to form gels in situ 
in response to a temperature increase [18-21]. However, they 
generally have a high critical gelation concentration (CGCs) and poor 
resilience [22], in addition, the hydrogels of poloxamer 407 formed 
above the sol gel transition temperature generally exhibit no or poor 
bioadhesive properties [23]. Therefore, formulating poloxamer 407 
with other bioadhesive polymers such hydroxyl-propyl-
methylcellulose (HPMC), will decrease the used concentration, 
increase its mucoadhesion and in turn enhance its ability to 
withstand salivation, tongue movements and swallowing for a 
significant period of time [24]. 
The aim of the study was to evaluate the impact of BZN-PLGA-NP-HG 
on the treatment of oral mucositis in vivo. 
MATERIALS AND METHODS 
Materials 
Benzydamine Hydrochloride, a kind gift from EIPICO, Egypt. 
Hydroxy propyl methyl cellulose, a kind gift from EIPICO, Egypt. 
Poloxamer 407, Purchased from Sigma, USA. Poly (lactic-co-glycolic) 
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polymer; 50:50 (PLGA 50:50) was a kind gift from PURAC Entrapment efficiency (EE) . Other 
materials were of analytical grade. 
Preparation of free (PLGA NPs) and BZN HCl loaded PLGA 
nanoparticles (BZN-PLGA-NPs) 
The porous PLGA nanoparticles loaded with BNZ HCl were prepared 
using the water–oil–water emulsion solvent evaporation method. 
Briefly, 100 mg PLGA were dissolved in 4 ml dichloromethane and 
placed in an ice bath, then 0.8 ml of distilled water was added to the 
PLGA solution dropwise. The resulting mixture was emulsified by 
ultra-sonication in an ice bath for 2 min, after which a solution of 
ammonium bicarbonate (100 mg/ml, 0.1 ml) was added and the mixture 
was re-sonicated in an ice bath for 30 s to form the primary emulsion. 
The primary emulsion was poured into 50 ml of poly-(vinyl alcohol) 
aqueous solution (0.5%, w/v) and homogenized at 3000 rpm in an ice 
bath for 3 min. The resulting emulsion was added to 50 ml of distilled 
water, and the dichloromethane was allowed to evaporate under 
magnetic stirring at room temperature over 5 h. Finally, the formed 
nanoparticles were collected by centrifugation at 5000 rpm for 15 min, 
washed with distilled water three times, and then lyophilized. The dried 
porous nanoparticles were stored at −20 °C until use. 
For the preparation of BNZ-PLGA-NPs, a specific amount of the drug 
equivalent to 0.15% w/v final concentration was added to distilled 
water before addition to the PLGA dichloromethane solution and 
further steps were continued as mentioned above. 
Characterization of PLGA nanoparticles  
Particle size, PDI and zeta potential 
The particle size, PDI and zeta potential of drug-free PLGA NPs and 
BNZ-PLGA-NPs were determined by dynamic light scattering (DLS) 
using a Zetasizer (Malvern Instrument, Worcestershire, UK). All 
samples were diluted with distilled water and equilibrated for 30 
min before measurement.  
A specific weight of freeze-dried BNZ-PLGA-NPs was soaked in 10 ml 
phosphate buffer for 30 min using bath sonicator. The solution was 
then centrifuged at 15000 rpm in at 15 °C for 30 min to remove 
polymeric debris. The supernatant was collected, and the polymeric 
debris were washed twice with fresh buffer to extract any adhered 
drug. The clear supernatant solution was then analyzed for its BZN 
content using UV spectrophotometer at λ max of 305 nm.  
Complete extraction of the drug was confirmed by repeating the 
extraction process on the already extracted polymeric debris. 
Entrapment efficiency was calculated by using the following equation:  
%EE =(Amount of drug initially used to prepare the PLGANPs )−(Amount of drug released from the PLGANPs) 
(Amount of drug initially used to prepare the PLGANPs)
∗ 100 
Preparation of HG bases 
Six different in situ gel formulations were prepared (table 1). PLX was 
used either alone (in three different concentrations) or in combination 
with HPMC in formulating HGs. Different weight ratios of PLX: HPMC 
were investigated to assess the effect of adding HPMC on the 
thermosensitive and mucoadhesive properties of PLX. For the 
preparation of PLX HGs (F0), 10 g Poloxamer 407 were dissolved in 50 
ml distilled water under magnetic stirring and left in the refrigerator for 
24 h. For the preparation of PLX/HPMC HG, HPMC was added in each 
specific concentration to the formed PLX HG, continuous stirring was 
applied till all components were completely dissolved and the formed 
hydrogel was left in the refrigerator for further 24 h.  
Preparation of BNZ-PLGA-NPs loaded hydrogel 
The BNZ-PLGA-NPs dispersion previously optimized was 
incorporated into the blank HG bases prepared using high speed 
stirring for 3 min at 1000 rpm, in a concentration of 50% (w/w) of 
the BNZ-PLGA-NPs dispersion into HG. The final concentration of 
BNZ in all BNZ-PLGA-NPs-HG formulation was set to 0.15% w/v.
 
Table 1: Composition of the prepared free HG formulations 
Formulation PLX (g) Drug Concentration (%) HPMC (g) 
F0 10 0.15 0 
F00 20 0.15 0 
F000 30 0.15 0 
F1 10 0.15 0.25 
F2 10 0.15 0.5 
F3 10 0.15 1 
 
Evaluation of hydrogel bases 
Scanning electron microscopy (SEM) 
The morphology of F3 BZN-PLGA-NPs-HG was examined using 
scanning electron microscopy (JSM-5900LV, JEOL, Japan). Before 
observation, the sample was freeze-dried and was cut-off with a 
treatment of liquid nitrogen. 
Thermosensitivity study 
The “gelation temperature” method was used to assess the 
temperature responsive gelation property of the prepared 
hydrogels. A sample solution was put in a 250 ml beaker, the beaker 
was then placed in a water bath heated slowly from 20 °C to 40 °C at 
an increment of 2 °C/step under magnetic stirring. The gelation 
point was determined using a stopwatch when the magnetic bar 
stopped rotating, the temperature at which the magnetic bar 
stopped moving was determined as the gelation temperature. 
To evaluate the effect of dilution by buccal saliva on the 
thermosensitive gelation capacity of the in situ BZN-PLGA-NPs-HGs, 
similar measurements as mentioned above were carried out but after 
mixing the hydrogel with simulated saliva fluid (SSF) at the volume 
ratio of 5:1. Simulated saliva was prepared according to the following 
composition 8 g/l sodium chloride, 0.19 g/lpotassium phosphate 
monobasic and 2.38 g/l sodium phosphate dibasic [25, 26]. 
Mucoadhesion evaluation 
Mucin-interaction method was used to evaluate the mucoadhesion 
properties of the prepared hydrogels through determining the 
changes in zeta potential. Porcine mucin powder was hydrated in 
demineralized water at 4 °C for 12 h. The mucin solution was then 
adjusted to pH 7.4 and diluted to a final concentration of 1% (w/v) 
using 0.1 M phosphate buffer (pH 7.4). The mucin solution was 
centrifugated at 5000 rpm for 30 min, the resulting supernatant was 
filtered and used in the mucoadhesion experiment. Equal volumes of 
each prepared hydrogel, one at a time, and the 1% (w/v) mucin 
particles solution were mixed using a vortex for 1 min. The zeta 
potential of each of the mucin solution and the mixtures was 
measured using Zetasizer and the changes in the zeta potential 
following interaction of the hydrogel with the negatively charged 
mucin [27] was investigated.  
In vitro drug release 
The in vitro release characteristics of BNZ HCl from HG matrix, 
PLGA-NPs and PLGA-NPs-HG were studied. Samples of each of the 
tested formulations containing predetermined drug content of 
0.15%w/w were placed first in a dialysis bag then in a dissolution 
apparatus containing 350 ml phosphate buffer of pH 6.8±0.5 at 
37±0.5 °C. The stirring speed was set to 50 rpm. Aliquots of 2 ml 
were withdrawn at previously specified time intervals and replaced 
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by equal volumes of fresh buffer solution. Samples were measured 
spectrophotometrically at λmax 305 nm [28]. 
In vivo animal study 
The in vivo protocol was carried out in accordance with the 
Guidelines laid down by the National Institute of Health (NIH) in the 
USA regarding the care and use of animals for experimental 
procedures and in accordance with local laws and regulations. 
Twenty-four male albino rabbits weighing 2.5–3.0 kg provided by 
the animal house of Assiut University, Egypt. Animal ethical 
approval was obtained from the Ethics Committee of the Faculty of 
Pharmacy, Al-Azhar University (approval code pharmaceut05) were 
used for this study. Animals have been acclimatized for one week. 
Each group of rabbits was placed in a separate cage with free access 
to food and drink. The cage environment was controlled to optimum 
humidity and 25 °C temperature. 
Oral mucositis was induced by cancer chemotherapy [29]. Rabbits 
were administered an intraperitoneal injection of 5-fluorouracil on 
5, 3 and 1 d prior to the experiment at a dose of 50 mg/kg body 
weight. On the day of the experiment, mice were anesthetized, and 
the model of oral mucositis was enhanced through creating aseptic 
tissue necrosis in all 24 animals using round filter paper soaked in 
15 ml of 50% acetic acid. In order to create round ulcers and 
facilitate measurements and follow up, the acid-soaked paper was 
pressed onto the labial gingival tissue of the rabbits for 60 s. Animals 
were divided into four groups, each of 6 animals; Group 1: Control 
group where animals received no treatment, Group 2: where 
animals received BZN-HG treatment, Group 3: where animals 
received BNZ-PLGA-NPs treatment and Group 4: where animals 
received BNZ-PLGA-NPs-HG treatment. The treatment started 24 h 
after ulcer initiation (day 1). The dose of BZN HCl used for groups 2 
and 3 was 1 mg/kg drug applied twice daily. The area of the ulcer 
measured on day 1 before treatment application was considered the 
baseline reading. The progress and healing of the buccal ulcer were 
evaluated by subtracting the daily reading from the ulcer 
measurement at day 1.  
Statistical analysis 
The statistical analysis was carried out using Graphpad Software 
Instat (version 6; GraphPad Software, Inc., La Jolla, CA, USA). The 
level of significance was set at probability *P<0.05. 
RESULTS AND DISCUSSION 
PLGA nanoparticles 
Free and BZN loaded PLGA nanoparticles were prepared and 
characterized for their physicochemical properties including particle 
size, PDI and zeta potential. BZN-PLGA-NPs were further 
characterized for their entrapment efficiency (%) (table 2). 
Experimental conditions for the preparation of PLGA nanoparticles 
including the sonication time and amplitude were optimized after 
preliminary trials (data not shown) to 100% amplitude and 12 min 
sonication time [30]. 
The particle size of BZN free PLGA-NPs was found to be 69.27 ± 5.19 
nm while that of BZN-PLGA-NPs was found to be a bit higher (90.81 
± 4.92 nm), similar particle size ranges for free and loaded PLGA NPs 
were previously reported [31, 32]. PDI showed uniform size 
distribution. Zeta potential of both free and BZN loaded PLGA-NPs 
were found to be-29.17 and-26.51, respectively indicating the 
formation of stable particles. Both formulations showed a negative 
charge with BZN-PLGA-NPs showing slightly lower values than free 
PLGA NPs. Negative values of zeta potential obtained for PLGA-NPs 
might be due to the presence of terminal carboxyl groups in the 
polymer. The percentage of incorporated BZN in the polymeric 
matrix was found to be 80% which agrees with the findings of 
Abrego et al., conducted in 2014 [33]. 
  
Table 2: Particle size, PDI, zeta potential and entrapment efficiency of PLGA-NPs 
 Free PLGA BZN-PLGA-NPs 
Particle Size (nm) 69.27 ± 5.19* 90.81± 4.92* 
PDI 0.197 0.265 
Zeta Potential (mv) -29.17 -26.51 
EE (%) - 79.92± 3.10* 
*Results are expresses as mean±SD, n=3. 
 
 
Fig. 1: SEM micrograph of BZN-PLGA-NPs-HGs 
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Preparation and characterization of PLX/HPMC HG 
HPMC together with PLX 407 were used in different w/w ratios to 
prepare a set of three different formulations of buccal in situ gels 
(table 1). BZN-PLGA-NPs were incorporated into different HG bases 
and the properties of BZN-PLGA-NPs-HGs were assessed. 
Scanning electron microscopy (SEM) 
Fig. 1 reveals the distribution of PLGA-NPs within the porous 
channels of HG matrix. SEM image shows the nanosized dimensions 
of PLGA-NPs. 
Thermosensitivity study  
According to the results shown in table 2, the gelation temperature 
of all BZN-PLGA-NPs-HGs ranged between 31°C and 36.5°C which 
renders them all suitable for buccal application [34]. However, it 
was obvious that the general range of gelation temperatures was 
higher for HGs formed of PLX solely which reflects the effect of 
mixing HPMC with PLX on reducing the gelation temperature. 
To study the effect of HPMC addition on minimizing the 
concentration of PLX used, different concentrations of HPMC were 
mixed with the lowest tested concentration of PLX (10 gm). 
Interestingly, gelation temperature of PLX/HPM Cmixtures (F1, F2 
and F3) were modulated to lower values compared to PLX solutions 
alone (F0, F00 and F00) which suggests that HPMC had a synergistic 
effect on the gelation of PLX. It has been previously reported that the 
incorporation of HPMC increased the elastic character of poloxamer 
gels and decreased their temperature of gelation [23]. PLX is a tri-
block copolymer which when present in aqueous solution and with 
increasing temperature, the hydrophobic chains of the copolymer 
undergo de-solvation due to the breaking of hydrogen bonds 
previously formed between the solvent and these chains. This 
promotes hydrophobic interactions among the polyoxypropylene 
domains and leads to gel formation [35] and at the definite point of 
gelation, micelles come into contact and organize under a micellar 
cubic phase [36] and no longer move. Micelle entanglements do not 
allow micelles to separate easily from each other and thus, forms 
rigid HG [37]. In the presence of HPMC, the HPMC chains might be 
able to bridge the poloxamer micelles, thus, leading to the formation 
of a network of interconnected micelles. This bridging might occur 
as early as micellization starts and even before the organization of 
the micelles under a cubic phase [23]. HPMC; through its highly 
hygroscopic nature, and its multiple hydroxyl functional groups, 
enhances the dehydration of PLX and, consequently the hydrophobic 
interactions between the poly-(propylene oxide) blocks. 
The BZN-PLGA-NPs-HG formulations were mixed with SSF to 
simulate expected dilution in the in vivo circumstances. As shown in 
table 3, when diluted with 1 ml SSF, all BZN-PLGA-NPs-HGs were 
found to preserve their gelation properties with non-significant 
differences in gelation temperature reported with any BZN-PLGA-
NPs-HG before and after addition of SSF (*p>0.05). All BZN-PLGA-
NPs-HGs retained gelation temperatures below 37 °C except for 
formula F0 containing 10% PLX/0% HPMC which showed a gelation 
temperature of 37.3 °C (table 3). 
 
Table 3: Gelation time measurements of different formulations 
Formulation PLX (gm) Drug concentration (%) HPMC (gm) Gelation* Gelation temp (°C) * temp after addition of SSF (°C) 
F0 10 0.15 0 36.5±0.45 37.3±1.16 
F00 20 0.15 0 35±0.84 35.6±0.28 
F000 30 0.15 0 34±0.79 34.5±1.29 
F1 10 0.15 0.25 32.5±0.73 33.3±0.65 
F2 10 0.15 0.5 32.5±1.01 33.2±0.82 
F3 10 0.15 1 31±0.91 32±0.63 
*Results are expressed as mean±SD, n=3. 
 
Mucoadhesion study 
As stated by Chatterjee and his colleagues in 2017, the success of 
mucoadhesive formulations depends on the ability of the polymer/s 
to retain at the mucous layer and to sustain the drug release [44]. 
Mucoadhesive formulations contain at least one hydrophilic 
polymer, when this polymer comes in contact to saliva, due to the 
aqueous nature of saliva, it is wetted, and simultaneously adheres to 
the mucous with some physical interaction [38]. The polymers 
employed in BNZ-PLGA-NPs-HG formulations have been denoted as 
mucoadhesive and, therefore, it would be anticipated that the 
formulation would display good adherence properties [39-40]. 
The mucin-particle method was used to evaluate the mucoadhesive 
properties of BZN-PLGA-NPs-HG formulations through measuring 
the changes in the zeta potential of mucin following the addition of 
different BZN-PLGA-NPs-HGs one at a time at pH 6.8. The in vitro 
mucoadhesion test confirmed that all formulations possessed 
mucoadhesive properties where a significant change (*P<0.5) in the 
zeta potential of mucin with BNZ-PLGA-NPs-HG compared to free 
mucin was reported for all formulations (table 4).  
Mucoadhesion was found lower for formulations prepared with PLX 
without HPMC i.e., F0, F00 and F000 with F0 containing 10 gm PLX/0 gm 
HPMC showing the lowest mucoadhesive property, however, an increase 
in the concentrations of PLX from 10 to 30% resulted in an increase in 
adhesion. On the other hand, the presence of HPMC with its known 
mucoadhesive characteristics [41] enhanced mucoadhesion with F3; 
containing the highest concentration of HPMC; showing the highest 
mucoadhesive property. It’s worth mentioning that the addition of 
HPMC to PLX enhanced the mucoadhesion property of the HG inspite of 
the lower concentration of PLX used which highlights the synergistic 
influence of the concomitant presence of PLX and HPMC in the HG. The 
mucoadhesive force increased in formulations F1, F2 and F3 with 
increasing HPMC concentration from 0.25% to 1% [42]. Cellulose 
derivatives such as HPMC are considered first generation mucoadhesive 
polymers [43], they acquire their adhesion property through the 
formation of H bond between the carboxylic acid group of the cellulose 
polymer and the glycoprotein of mucin. As the concentration of HPMC in 
the formulation increases, stronger H bonds are formed causing deeper 
and stronger attachment of the HG with the mucous layer [44]. 
Mucoadhesion results are likely to ensure a prolonged adhesion of the 
HGs at the mucosal surface, following their buccal administration. 
 
Table 4: Effect of the interaction of hydrogel and mucin on Zeta potential 
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In vitro drug release 
The release of drug from three different formulations was 
performed; HG, PLGA-NPs and PLGA-NPs-HG. Based on the thermo 
sensitivity and mucoadhesion results, the HG composed of 10 g PLX 
and 1 g HPMC was selected as the base of HG and PLGA-NPs-HG 
formulations used in the in vitro release experiment.  
As shown in fig. 2, both PLGA-NPs and PLGA-NPs-HG formulations 
offered a slower release of BZN when compared to HG. PLGA-NPs-
HG provided the slowest release of BZN amongst the three tested 
formulations. The fact that PLGA-NPs were retained within the 
PLX/HPMC HG matrix might have influenced the release profile of 
BZN and reduced the initial burst release of the drug molecules [45]. 
Both PLGA-NPs and PLGA-NPs-HG provided a similar biphasic drug 
release profile [46]. Compared to BZN-PLGA-NPs, BZN-PLGA-NPs-
HG showed a reduced burst release (30.81 at 1.5 vs 19.6% at 1h, 
respectively). BZN release from BZN-PLGA-NPs occurred according 
to two phases. In phase I, the dissolution medium stimulated the 
release of the drug molecules adsorbed on the surface of the NPs 
through desorption of particles, in addition, it caused the random 
break of the polymeric structure causing a reduction in the 
molecular weight of the polymer. In phase II, a combined 
erosion/diffusion mechanism took place where the erosion of a 
thicker polymer layer occurred to allow the diffusion of the drug 
particles in a slower release rate. For PLGA-NPs-HG, the three-
dimensional network structure of hydrogels is expected to further 
delay the release of the drug [47] as the release into the medium is 
expected to occur in two steps, first the release of the drug from the 
PLGA-NPs as per the steps mentioned above then the drug followed 
by drug diffusion through the microchannels of the hydrogel to the 
external media.  
From the analysis of the release profiles (fig. 2), BZN-HG showed 
faster drug release in comparison to BZN-PLGA-NPs-HGs, in 
addition, a monophasic zero order release pattern (R2
After four hours the HG with free BZN exhibited a drug release of 
71.26%, while for BNZ-PLGA-NPs-HG, the maximum amount 
released was 45.99 %. These results evidenced the ability of PLGA-
NPs-HG to offer a sustained drug release of BZN thus, maintaining its 
presence for a longer time over the affected buccal area. In the study 
conducted by Ashmoony et al., incorporation of clomipramine in 
niosomal gel lead to a delayed drug release profile which the authors 
attributed to the presence of additional diffusion barrier [49]. 
= 0.9874) was 
reported. In the study conducted by Kassab et al., in 2017, a biphasic 
release profile was reported for gatifloxacin from periodontal 
bioadhesive gel. The authors attributed the initial burst effect to the 
drug which is present freely in the gel matrix [48]. 
 
 
Fig. 2: Drug release profile of BZN from HG, PLGA-NPs and PLGA-NPs-HG (Results are expressed as mean±SE, n=3) 
 
In vivo study 
In order to determine the efficacy of tested formulations on the 
clinical healing of oral mucositis, the ulcer area was measured on 
consequent observation days and percentage reduction was 
recorded. The mucositis model used was adapted from Takeuchi et 
al., 2018 and Karavanaet al., 2011 [50-51]. 
In the present study, the most prominent differences between the 
groups were observed on day 2. The untreated group showed a 
worsened ulcer condition. Animal groups 2 and 4 treated with 
BZN-HG and BZN-PLGA-NPs-HG, respectively showed a 
significantly higher reduction percentage in ulcer surface area 
compared to group 3 treated with BZN-PLGA-NPs (*p<0.05), 
which suggests that both treatments may promote early stage 
healing [50]. 
The BZN-PLGA-NPs-HG group 4 needed 10 d of treatment to complete 
healing versus 16 d, 14 d and 12 d for the complete healing of groups 
1(no treatment), 3 (treated with BZN-PLGA-NPs) and 2 (BZN-HG). 
From these results (table 5), the high retention in the oral cavity of BZN-
PLGA-NPs-HG could be considered the main factor contributing to its 
enhanced therapeutic outcome. BZN-PLGA-NPs with non-retentive 
properties showed the lowest reduction percentage on day 2 and the 
longest treatment period compared to the other two formulations. BZN-
HG did not contribute to shortening the treatment period of oral 
mucositis, however, they helped reduce the ulcer area. 
  
Table 5: Average reduction in ulcer surface area for rabbits in different test groups 









41.83±3.23 17.29±1.29 39.82±2.39 -34.12±1.29 Day 2 
60.49±1.83 39.85±2.19 45.19±3.20 -5.67±0.21 Day 4 
75.50±2.01 48.39±2.71 61.10±1.93 7.20±0.88 Day 6 
93.02±4.32 65.30±4.38 74.84±5.83 29.10±2.10 Day 8 
 83.24±3.28 89.28±3.29 48.33±3.29 Day 10 
95.29±6.49  70.17±2.93 Day 12 
 92.10±4.85 Day 14 
100±5.40 Day 16 
P
*
PResults are expressed as mean±SD, n=6. 
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CONCLUSION  
In the present study, PLGA nanoparticles were prepared, drug 
loaded and incorporated into six different PLX/HPMC HGs. F3 BZN-
PLGA-NPs-HGs showed promising thermosensitive, mucoadhesive 
and in vitro release properties and when tested on experimental 
animals’ model, it was able to successfully contribute to the effective 
treatment of mucositis in a reduced time interval. 
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